Partnership to Improve Patient Care

  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Patient Access
    • Value Our Health
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • Blog
    • PIPC Patients' Blog
    • Chairman's Corner
    • PIPC Weekly Update
    • The Data Mine
  • Newsroom
    • PIPC in the News
    • Press Releases
    • Open Letter: We Deserve a Voice
  • Events
    • PIPC Forum 2020
    • C & GT Webinar
    • ICER COVID Webinar
    • Value Our Health Briefing
    • QALY Briefing
    • QALY Panel
    • Past Webinars >
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Patient Access
    • Value Our Health
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • Blog
    • PIPC Patients' Blog
    • Chairman's Corner
    • PIPC Weekly Update
    • The Data Mine
  • Newsroom
    • PIPC in the News
    • Press Releases
    • Open Letter: We Deserve a Voice
  • Events
    • PIPC Forum 2020
    • C & GT Webinar
    • ICER COVID Webinar
    • Value Our Health Briefing
    • QALY Briefing
    • QALY Panel
    • Past Webinars >
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010

The PIPC Blog

IHP: Without Rebates, Evidence Could Be Key For Formulary Placement

4/18/2019

 
Picture
In an article for Inside Health Policy, Partnership to Improve Patient Care (PIPC) Executive Director Sara van Geertruyden highlighted concerns from patient advocates about the use of comparative effectiveness data being used to limit patient access to drugs. She pointed out the problems with a "one-size-fits-all" approach, touting the Patient Centered Outcomes Research Institute's (PCORI) approached to comparative effectiveness research over the payer-focused approach taken by the Institute for Clinical and Economic Review (ICER). “Comparative effectiveness improves decision making by making sure the right patient gets the right treatment at the right time," said van Geertruyden. "But when you are talking about allowing coverage decisions based on averages to drive health care decision-making for individual patients, you allow payers and governments to drive one-size-fits-all decisions for patients." 

The article in its entirety can be read below. 
Without Rebates, Evidence Could Be Key For Formulary Placement
April 18, 2019
 
Information about a drug’s effectiveness compared to alternative treatments could help drug makers argue for formulary placement in a system without rebates, Deloitte’s head of life sciences said. Some patient advocates worry that using comparative effectiveness data in coverage decisions could limit access, as different drugs work better for different patients.
 
Greg Reh, Deloitte’s vice chairman and leader of its life science division, said the Trump administration’s point-of-sale rebate proposal could force drug companies to compete more directly on value.
 
“This might require a shift in strategy toward more robust evidence generation, the development of support services, and greater competition in value-based contracts,” Reh wrote in an analysis.
 
He recommends that drug makers evaluate additional outcomes beyond what is required by FDA to prove their product’s superiority compared to other drugs, study effectiveness in patient sub-populations and add strategies to help patient adherence and convenience.
Congressional Medicare advisers recently discussed using reference pricing based on comparative effectiveness evidence to develop payment policy in Medicare Part B, though some commissioners still consider the idea too controversial to pursue in the immediate future.
Some patient advocates are concerned about comparative effectiveness data being used to limit patient access to medications, as different patients have different reactions to the same drugs and devices.
 
“Comparative effectiveness improves decision making by making sure the right patient gets the right treatment at the right time. But when you are talking about allowing coverage decisions based on averages to drive health care decision-making for individual patients, you allow payers and governments to drive one-size-fits-all decisions for patients,” said Sara van Geertruyden, executive director of the Partnership to Improve Patient Care.
 
Groups that conduct comparative effectiveness and cost-effectiveness analyses hold significant sway over coverage decisions in other countries such as the United Kingdom and Canada. The influence of similar organizations has been limited in the United States but is increasing as pressure mounts to address high drug prices.
 
Lawmakers created a government-sponsored organization to conduct comparative effectiveness research, the Patient-Centered Outcomes Research Institute, in the Affordable Care Act. Medicare is allowed to factor PCORI’s research into decisions of which drugs to cover, though there are some restrictions.
 
The name of the institute was changed while it was being debated in Congress from the Comparative Effectiveness Research Institute to PCORI.
 
“Comparative effectiveness research went through a phase where it was linked in some people's minds to rationing, to cost-effectiveness measurement, and had transiently acquired a dubious name,” Joseph Selby, the first executive director of PCORI, told Medscape in 2012.
 
Selby has announced his retirement at the end of this year.
 
To avoid being associated with the negative connotations around rationing, Center for Medical Technology Policy Founder Sean Tunis said PCORI avoided addressing costs, cost-effectiveness and largely payers.
 
“The problem with that is that one of the original inspirations for setting this up was helping people make cost-conscious decisions in the face of unsustainable spending trend. So it narrowed the space in which PCORI felt comfortable initially operating,” Tunis said at an Alliance for Health Policy briefing.
 
Van Geertruyden said she thinks that the PCORI statute was developed carefully, and prefers the group’s approach to that taken by the Institute for Clinical and Economic Review, which she characterizes as geared toward payers instead of patient decision-making.
 
Unlike PCORI, ICER uses Quality-Adjusted Life Year measurements, which have been controversial in the United States, in its cost-effectiveness analysis. ICER pitches itself as an independent drug pricing watchdog that produces cost-effectiveness and budgetary impact reports to inform policy decisions. ICER did not respond to a request for comment.
 
A recent ICON white paper found ICER is becoming more influential as a decision-making resource for payers.
 
“We also know that contracting negotiations will be significantly impacted by ICER assessments going forward -- and that manufacturers will need to be prepared to reconcile their economic evaluations with ICER’s assessments,” ICON wrote. -- Rachel Cohrs

​(rcohrs@iwpnews.com)

Comments are closed.

    Topics

    All
    Alternative Payment Models
    Chairman's Corner
    Patient Centered Research
    PIPC In The News
    PIPC Patient Blog
    PIPC Weekly Update
    Press Releases
    The Data Mine
    Value Frameworks

    Archives

    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    April 2013
    March 2013
    December 2012
    November 2012
    February 2012
    September 2011
    August 2011
    July 2011
    May 2011
    March 2011
    November 2010
    October 2010
    September 2010
    August 2010
    April 2010
    March 2010
    February 2010
    December 2009
    September 2009
    July 2009
    June 2009
    May 2009
    February 2009
    January 2009
    December 2008

About PIPC
The Issues
Resources
Blog
In the News
Press Releases
Contact Us
100 M Street, SE – Ste. 750
Washington, DC 20003